News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Actient Pharmaceuticals LLC Acquires U.S. Rights to STRIANT from Columbia Laboratories, Inc. (CBRX)



4/21/2011 10:39:11 AM

LIVINGSTON, N.J.--(BUSINESS WIRE)--Columbia Laboratories, Inc. (Nasdaq: CBRX) has entered into an asset purchase agreement with Actient Pharmaceuticals LLC (“Actient”), a privately-held specialty therapeutics company, for STRIANT® (testosterone buccal system) in the United States.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES